Presbyopia is a highly prevalent age-related condition that can significantly compromise near vision in adults. If left uncorrected, presbyopia can notably impact a patient's quality of life. Estimates published in the American Journal of Ophthalmology indicate that approximately one in eight U.S. adults aged 50 and older exhibits near-vision impairment attributed to presbyopia. Given the substantial impact of the condition, familiarity with current clinical guidelines, FDA-approved options, and emerging interventions under investigation in clinical trials is essential for optimizing patient management and improving outcomes.

Current Presbyopia Guidelines

There are currently no recently published/updated clinical guidelines focusing specifically on presbyopia. However, the American Optometric Association (AOA) does briefly mention it in its 2023 evidence-based clinical practice guideline, linked below. Also linked below is the 2023 American Academy of Ophthalmology (AAO) guidelines on refractive surgery, which include some recommendations regarding the surgical management of presbyopia.

Comprehensive Adult Eye and Vision Examination

  • American Optometric Association (AOA)
  • March 2023

Refractive Surgery Preferred Practice Pattern

  • American Academy of Ophthalmology (AAO)
  • March 2023
Recent FDA Approvals for Presbyopia

Below are the most recent approvals by the FDA that we anticipated may be incorporated into future clinical guidelines: 

Vizz Eye Drops (aceclidine)

  • LENZ Therapeutics
  • Approved: July 2025
  • Vizz is the first and only FDA-approved aceclidine-based eye drop for adults with presbyopia.

Qlosi (pilocarpine hydrochloride ophthalmic solution)

  • Orasis Pharmaceuticals
  • Approved: October 2023
  • Qlosi is a prescription eye drop that lasts up to eight hours to improve near vision in adults with presbyopia.
Ongoing Clinical Trials Related to Presbyopia

The following are ongoing, Phase 3 clinical trials based in the United States that we anticipate may impact future presbyopia clinical guidelines.

Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia

  • Ocuphire Pharma, Inc.
  • Anticipated Completion: May 2026

Phase III Presbyopia Correction Using the VIS Opti-K™ System

  • VIS, Inc.
  • Anticipated Completion: December 2027

Sign up for alerts to keep up with the latest guidelines and insights.

Copyright © 2025 Guideline Central, all rights reserved.